Theratechnologies Inc., of Montreal, announced a new clinical program for muscle wasting in chronic obstructive pulmonary disease (COPD) using the company's lead compound, tesamorelin, a human growth hormone releasing factor analogue. The company said it will develop tesamorelin in muscle wasting in patients with COPD as its second indication.